目次

1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE
1.3.2 INCLUSIONS & EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.3.4 CURRENCY CONSIDERED
1.4 STAKEHOLDERS
1.5 SUMMARY OF CHANGES

2 EXECUTIVE SUMMARY
2.1 KEY INSIGHTS & MARKET HIGHLIGHTS
2.2 KEY MARKET PARTICIPANTS: INSIGHTS & STRATEGIC DEVELOPMENTS
2.3 DISRUPTIVE TRENDS SHAPING PREIMPLANTATION GENETIC TESTING MARKET
2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS
2.5 GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SNAPSHOT

3 PREMIUM INSIGHTS
3.1 NORTH AMERICA: PREIMPLANTATION GENETIC TESTING MARKET, BY PRODUCT & SERVICE AND COUNTRY
3.2 PREIMPLANTATION GENETIC TESTING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
3.3 PREIMPLANTATION GENETIC TESTING MARKET SHARE, BY PRODUCT &
SERVICE, 2025 VS. 2030 (%)
3.4 PREIMPLANTATION GENETIC TESTING MARKET SHARE, BY END USER, 2024 (%)

4 MARKET OVERVIEW
4.1 INTRODUCTION
4.2 MARKET DYNAMICS
4.2.1 DRIVERS
4.2.1.1 Decline in fertility rates
4.2.1.2 Expanding network of fertility clinics and IVF centers
4.2.1.3 Rising incidence of chromosomal abnormalities associated with advancing maternal age
4.2.2 RESTRAINTS
4.2.2.1 High procedural cost
4.2.2.2 Stringent regulatory frameworks governing IVF and genetic testing procedures
4.2.3 OPPORTUNITIES
4.2.3.1 Expanding acceptance of fertility treatments among single parents and same-sex couples
4.2.4 CHALLENGES
4.2.4.1 Socio-ethical concerns regarding embryo screening and selection
4.3 UNMET NEEDS & WHITE SPACES
4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
4.5 STRATEGIC MOVIES BY TIER-1/2/3 PLAYERS

5 INDUSTRY TRENDS
5.1 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS
5.2 MACROECONOMIC OUTLOOK
5.2.1 GDP TRENDS & FORECAST
5.2.2 R&D TRENDS IN GLOBAL HEALTHCARE INDUSTRY
5.2.3 R&D TRENDS IN GLOBAL PHARMA INDUSTRY
5.3 CASE STUDY ANALYSIS
5.3.1 PGT-M FOR RPGRIP1L VARIANT-ENABLED BY MINIGENE ASSAY
5.3.2 PERSISTENT FETAL MOSAICISM AFTER TRANSFER OF PGT-A MOSAIC EMBRYO
5.3.3 CRYPTIC REARRANGEMENTS RESOLVED BY OGM TO GUIDE PGT-SR
5.4 PRICING ANALYSIS
5.4.1 AVERAGE SELLING PRICE TREND OF PREIMPLANTATION GENETIC TESTING PRODUCTS, BY END USER, 2022−2024
5.4.2 AVERAGE SELLING PRICE TREND OF PREIMPLANTATION GENETIC TESTING PRODUCTS, BY KEY PLAYER, 2022-2024
5.4.3 AVERAGE SELLING PRICE TREND OF PREIMPLANTATION GENETIC TESTING PRODUCTS, BY PROCEDURE TYPE, 2022−2024
5.4.4 AVERAGE SELLING PRICE TREND OF PREIMPLANTATION GENETIC TESTING INSTRUMENTS AND CONSUMABLES, BY REGION, 2022-2024
5.5 TRADE ANALYSIS
5.5.1 IMPORT DATA FOR HS CODE 3822, 2020-2024
5.5.2 EXPORT DATA FOR HS CODE 3822, 2020-2024
5.5.3 IMPORT DATA FOR HS CODE 9018, 2020-2024
5.5.4 EXPORT DATA FOR HS CODE 9018, 2020-2024
5.6 VALUE CHAIN ANALYSIS
5.7 ECOSYSTEM ANALYSIS
5.7.1 ROLE IN ECOSYSTEM
5.8 PORTER’S FIVE FORCES ANALYSIS
5.8.1 INTENSITY OF COMPETITIVE RIVALRY
5.8.2 BARGAINING POWER OF SUPPLIERS
5.8.3 BARGAINING POWER OF BUYERS
5.8.4 THREAT OF SUBSTITUTES
5.8.5 THREAT OF NEW ENTRANTS
5.9 KEY CONFERENCES & EVENTS, 2025-2026
5.10 INVESTMENT & FUNDING SCENARIO
5.11 IMPACT OF 2025 US TARIFF ON PREIMPLANTATION GENETIC TESTING MARKET
5.11.1 KEY TARIFF RATES
5.11.2 PRICE IMPACT ANALYSIS
5.11.3 KEY IMPACTS ON VARIOUS REGIONS
5.11.3.1 US
5.11.3.2 Europe
5.11.3.3 Asia Pacific
5.11.4 END-USE INDUSTRY IMPACT
5.11.4.1 Fertility clinics
5.11.4.2 Hospitals
5.11.4.3 Diagnostic laboratories

6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS
6.1 TECHNOLOGY ANALYSIS
6.1.1 KEY TECHNOLOGIES
6.1.1.1 Laser-assisted TE biopsy
6.1.1.2 Whole genome amplification
6.1.2 COMPLEMENTARY TECHNOLOGIES
6.1.2.1 Micromanipulation
6.2 TECHNOLOGY ROADMAP
6.3 PATENT ANALYSIS
6.3.1 METHODOLOGY
6.3.2 NUMBER OF PATENTS FILED, BY DOCUMENT TYPE
6.3.3 LIST OF KEY PATENTS
6.4 FUTURE APPLICATIONS
6.5 IMPACT OF AI/GEN AI ON PREIMPLANTATION GENETIC TESTING MARKET
6.5.1 TOP USE CASES AND MARKET POTENTIAL
6.5.2 BEST PRACTICES IN AI-ENABLED EMBRYO SELECTION AND GENETIC SCREENING
6.5.3 CASE STUDIES OF AI IMPLEMENTATION IN PREIMPLANTATION GENETIC TESTING MARKET
6.5.4 INTERCONNECTED ADJACENT ECOSYSTEM AND IMPACT ON MARKET PLAYERS
6.5.5 CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN PREIMPLANTATION GENETIC TESTING MARKET

7 SUSTAINABILITY & REGULATORY LANDSCAPE
7.1 REGIONAL REGULATIONS & COMPLIANCE
7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES & OTHER ORGANIZATIONS
7.1.2 INDUSTRY STANDARDS
7.1.2.1 North America
7.1.2.1.1 US
7.1.2.1.2 Canada
7.1.2.2 Europe
7.1.2.3 Asia Pacific
7.1.2.3.1 Japan
7.1.2.3.2 China
7.1.2.3.3 India
7.1.2.4 Latin America
7.1.2.4.1 Brazil
7.2 SUSTAINABILITY IMPACT & REGULATORY POLICY INITIATIVES
7.3 CERTIFICATIONS, LABELING, AND ECO-STANDARDS

8 CUSTOMER LANDSCAPE & BUYER BEHAVIOUR
8.1 DECISION-MAKING PROCESS
8.2 BUYER STAKEHOLDERS & BUYING EVALUATION CRITERIA
8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS
8.2.2 KEY BUYING CRITERIA
8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES
8.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES

9 PREIMPLANTATION GENETIC TESTING MARKET, BY PRODUCT & SERVICE
9.1 INTRODUCTION
9.2 REAGENTS & CONSUMABLES
9.2.1 EXPANSION OF ADVANCED GENOMIC TECHNOLOGIES TO PROMOTE MARKET GROWTH
9.3 INSTRUMENTS
9.3.1 ONGOING TECHNOLOGICAL ADVANCEMENTS AND INCREASING FERTILITY CLINICS TO PROPEL MARKET GROWTH
9.4 SOFTWARE & SERVICES
9.4.1 RISING AWARENESS ABOUT DATA ANALYSIS TO DRIVE MARKET

10 PREIMPLANTATION GENETIC TESTING MARKET, BY PROCEDURE TYPE
10.1 INTRODUCTION
10.2 PREIMPLANTATION GENETIC SCREENING
10.2.1 INCREASING MATERNAL AGE TO AID MARKET GROWTH
10.3 PREIMPLANTATION GENETIC DIAGNOSIS
10.3.1 RISING AWARENESS ABOUT CHROMOSOMAL ABNORMALITIES IN FETUSES TO SUPPORT MARKET GROWTH

11 PREIMPLANTATION GENETIC TESTING MARKET, BY TECHNOLOGY
11.1 INTRODUCTION
11.2 NEXT-GENERATION SEQUENCING
11.2.1 IMPROVED TECHNOLOGY FOR DETECTING STRUCTURAL ABNORMALITIES TO FUEL MARKET GROWTH
11.3 POLYMERASE CHAIN REACTION
11.3.1 INCREASED USAGE IN CLINICAL AND RESEARCH APPLICATIONS AND HIGH PREVALENCE OF GENETIC DISEASES TO SUPPORT MARKET
11.4 FLUORESCENCE IN SITU HYBRIDIZATION
11.4.1 ADVANCES IN FLUORESCENCE MICROSCOPY AND DIGITAL IMAGING TO AUGMENT MARKET GROWTH
11.5 COMPARATIVE GENOMIC HYBRIDIZATION
11.5.1 LOW COST, LESS LABOR REQUIREMENT, AND ONGOING TECHNOLOGICAL ADVANCEMENTS TO DRIVE MARKET
11.6 SINGLE-NUCLEOTIDE POLYMORPHISM
11.6.1 HIGH-RESOLUTION ACCURACY AND VALIDATED CLINICAL PERFORMANCE TO BOOST MARKET GROWTH

12 PREIMPLANTATION GENETIC TESTING MARKET, BY APPLICATION
12.1 INTRODUCTION
12.2 ANEUPLOIDY
12.2.1 HIGH ANEUPLOIDY INCIDENCE AND RAPID INNOVATION TO ACCELERATE MARKET GROWTH
12.3 STRUCTURAL CHROMOSOMAL ABNORMALITIES
12.3.1 TRANSLOCATIONS
12.3.1.1 Rising incidence of translocation chromosomal abnormalities during IVF treatments to drive segment
12.3.2 DELETIONS
12.3.2.1 Advancements in genetic testing to boost segment growth
12.3.3 DUPLICATIONS
12.3.3.1 Rising cases of duplication of chromosomal abnormalities and increasing maternal age to drive segment
12.3.4 INVERSIONS
12.3.4.1 Risk of unexplained male‐factor infertility and multiple miscarriages to limit segment growth
12.4 SINGLE GENE DISORDERS
12.4.1 INCREASING AWARENESS ABOUT GENETIC TESTING TO PROPEL MARKET GROWTH
12.5 X-LINKED DISORDERS
12.5.1 MEDICAL ADVANCEMENTS AND INCREASED RESEARCH ON GENETIC DISORDERS TO AUGMENT MARKET GROWTH
12.6 HLA TYPING
12.6.1 RISING NUMBER OF COUPLES WITH CHILDREN AFFECTED BY HEMATOLOGICAL DISEASES TO DRIVE MARKET
12.7 GENDER IDENTIFICATION
12.7.1 INCREASED FOCUS ON SEX DISCRIMINATION TO LIMIT MARKET GROWTH

13 PREIMPLANTATION GENETIC TESTING MARKET, BY TYPE OF CYCLE
13.1 INTRODUCTION
13.2 FRESH NON-DONOR
13.2.1 HIGH RATES OF SUCCESSFUL PREGNANCY AMONG YOUNG WOMEN TO DRIVE MARKET GROWTH
13.3 FROZEN NON-DONOR
13.3.1 LONG-TERM STORAGE OF FROZEN EGGS AND EASY SCHEDULING
TO PROPEL MARKET GROWTH
13.4 FRESH DONOR
13.4.1 HIGH-QUALITY FRESH DONOR OOCYTES AND EXPANDING PGT-DRIVEN RISK REDUCTION TO PROMOTE MARKET GROWTH
13.5 FROZEN DONOR
13.5.1 RISING USE OF ADVANCED AND NON-INVASIVE PGT TECHNOLOGIES
TO AID MARKET GROWTH

14 PREIMPLANTATION GENETIC TESTING MARKET, BY END USER
14.1 INTRODUCTION
14.2 FERTILITY CLINICS
14.2.1 HIGH SUCCESS RATE OF FERTILITY TREATMENT TO DRIVE MARKET
14.3 DIAGNOSTIC LABORATORIES
14.3.1 IMPROVED CLINICAL EFFICACY AND INCREASED RESEARCH FUNDING TO FUEL MARKET
14.4 HOSPITALS
14.4.1 RISING NUMBER OF HOSPITALS AND INCREASING HEALTHCARE AWARENESS TO DRIVE GROWTH
14.5 OTHER END USERS

15 PREIMPLANTATION GENETIC TESTING MARKET, BY REGION
15.1 INTRODUCTION
15.2 NORTH AMERICA
15.2.1 US
15.2.1.1 US to dominate North American preimplantation genetic testing market during forecast period
15.2.2 CANADA
15.2.2.1 Whole-genome embryo testing and public-private R&D investment to propel market growth
15.3 EUROPE
15.3.1 GERMANY
15.3.1.1 Global clinical adoption of precision medicines to boost market growth
15.3.2 UK
15.3.2.1 Demographic pressures and evidence-based clinical innovation to support market growth
15.3.3 FRANCE
15.3.3.1 Ethical regulation and adoption of patient-centered precision medicines to fuel market growth
15.3.4 ITALY
15.3.4.1 Regulatory reforms and clinical-genetic partnerships to boost market growth
15.3.5 SPAIN
15.3.5.1 Well-established network of research centers and universities to augment market growth
15.3.6 REST OF EUROPE
15.4 ASIA PACIFIC
15.4.1 CHINA
15.4.1.1 Advancing next-generation genomic infrastructure and cross-border fertility capacity to propel market growth
15.4.2 JAPAN
15.4.2.1 Reinforcing global PGT standards and rigorous clinical governance to favor market growth
15.4.3 INDIA
15.4.3.1 Expanding genetic-diagnostic access to drive market growth
15.4.4 AUSTRALIA
15.4.4.1 Standardized regulation and expanding clinical adoption to fuel market growth
15.4.5 SOUTH KOREA
15.4.5.1 Clinically validated PGT-A integration and improved IVF outcomes to support market growth
15.4.6 REST OF ASIA PACIFIC
15.5 LATIN AMERICA
15.5.1 BRAZIL
15.5.1.1 Global genomic innovation and regulatory modernization to boost market growth
15.5.2 MEXICO
15.5.2.1 Adoption of advanced NGS-based PGT services to support growth
15.5.3 REST OF LATIN AMERICA
15.6 MIDDLE EAST
15.6.1 GCC COUNTRIES
15.6.1.1 Kingdom of Saudi Arabia
15.6.1.1.1 Rising global emphasis on preventive genomic medicine and advanced embryo-screening technologies to drive market
15.6.1.2 UAE
15.6.1.2.1 Rising global demand for safer and technologically advanced embryo screening to aid market growth
15.6.1.3 Rest of GCC Countries
15.6.2 REST OF MIDDLE EAST
15.7 AFRICA
15.7.1 REGIONAL ART REGISTRY EXPANSION AND RISING IVF INFRASTRUCTURE TO PROPEL MARKET GROWTH

16 COMPETITIVE LANDSCAPE
16.1 INTRODUCTION
16.2 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN PREIMPLANTATION GENETIC TESTING MARKET
16.3 REVENUE ANALYSIS, 2020-2024
16.4 MARKET SHARE ANALYSIS, 2024
16.5 COMPANY VALUATION & FINANCIAL METRICS
16.5.1 FINANCIAL METRICS
16.5.2 COMPANY VALUATION
16.6 BRAND/PRODUCT COMPARISON
16.6.1 ILLUMINA, INC.
16.6.2 THERMO FISHER SCIENTIFIC INC.
16.6.3 AGILENT TECHNOLOGIES, INC.
16.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
16.7.1 STARS
16.7.2 EMERGING LEADERS
16.7.3 PERVASIVE PLAYERS
16.7.4 PARTICIPANTS
16.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
16.7.5.1 Company footprint
16.7.5.2 Region footprint
16.7.5.3 Product & service footprint
16.7.5.4 Technology footprint
16.7.5.5 Application footprint
16.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
16.8.1 PROGRESSIVE COMPANIES
16.8.2 RESPONSIVE COMPANIES
16.8.3 DYNAMIC COMPANIES
16.8.4 STARTING BLOCKS
16.8.5 COMPETITIVE BENCHMARKING
16.8.5.1 Detailed list of key startups/SMEs
16.8.5.2 Competitive benchmarking of key startups/SMEs
16.9 COMPETITIVE SCENARIO
16.9.1 PRODUCT LAUNCHES
16.9.2 DEALS
16.9.3 EXPANSIONS

17 COMPANY PROFILES
17.1 KEY PLAYERS
17.1.1 ILLUMINA, INC.
17.1.1.1 Business overview
17.1.1.2 Products/Services/Solutions offered
17.1.1.3 Recent developments
17.1.1.3.1 Deals
17.1.1.4 MnM view
17.1.1.4.1 Key strengths
17.1.1.4.2 Strategic choices
17.1.1.4.3 Weaknesses & competitive threats
17.1.2 THERMO FISHER SCIENTIFIC INC.
17.1.2.1 Business overview
17.1.2.2 Products/Services/Solutions offered
17.1.2.3 Recent developments
17.1.2.3.1 Product launches
17.1.2.4 MnM view
17.1.2.4.1 Key strengths
17.1.2.4.2 Strategic choices
17.1.2.4.3 Weaknesses & competitive threats
17.1.3 AGILENT TECHNOLOGIES, INC.
17.1.3.1 Business overview
17.1.3.2 Products/Services/Solutions offered
17.1.3.3 MnM view
17.1.3.3.1 Key strengths
17.1.3.3.2 Strategic choices
17.1.3.3.3 Weaknesses & competitive threats
17.1.4 REVVITY
17.1.4.1 Business overview
17.1.4.2 Products/Services/Solutions offered
17.1.4.3 MnM view
17.1.4.3.1 Key strengths
17.1.4.3.2 Strategic choices
17.1.4.3.3 Weaknesses & competitive threats
17.1.5 COOPERCOMPANIES
17.1.5.1 Business overview
17.1.5.2 Products/Services/Solutions offered
17.1.5.3 MnM view
17.1.5.3.1 Key strengths
17.1.5.3.2 Strategic choices
17.1.5.3.3 Weaknesses & competitive threats
17.1.6 ABBOTT
17.1.6.1 Business overview
17.1.6.2 Products/Services/Solutions offered
17.1.7 TAKARA BIO INC.
17.1.7.1 Business overview
17.1.7.2 Products/Services/Solutions offered
17.1.8 QIAGEN
17.1.8.1 Business overview
17.1.8.2 Products/Services/Solutions offered
17.1.9 VITROLIFE
17.1.9.1 Business overview
17.1.9.2 Products/Services/Solutions offered
17.1.10 OXFORD NANOPORE TECHNOLOGIES PLC
17.1.10.1 Business overview
17.1.10.2 Products/Services/Solutions offered
17.1.10.3 Recent developments
17.1.10.3.1 Expansions
17.2 OTHER PLAYERS
17.2.1 OXFORD GENE TECHNOLOGY IP LIMITED
17.2.2 YIKON GENOMICS
17.2.3 SHIVA SCIENTIFIC
17.2.4 NANJING SUPERYEARS GENE TECHNOLOGY CO., LTD.
17.2.5 MEDICOVER GENETICS
17.2.6 MEDGENOME
17.2.7 FULGENT GENETICS
17.2.8 INVICTA SP. Z O.O.
17.2.9 GENEA PTY LIMITED
17.2.10 SCIGENE CORPORATION
17.2.11 BIOARRAY S.L.
17.2.12 UNIMED BIOTECH (SHANGHAI) CO., LTD.
17.2.13 GENEMIND BIOSCIENCES CO., LTD.
17.2.14 BERRY GENOMICS
17.2.15 BANGKOK GENOMICS INNOVATION

18 APPENDIX
18.1 DISCUSSION GUIDE
18.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
18.3 CUSTOMIZATION OPTIONS
18.4 RELATED REPORTS
18.5 AUTHOR DETAILS